3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
4
Multiple Myeloma
2
Lymphoma
2
Glioma
2
Whooping Cough
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumococcal Infections
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Measles
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Human Papillomavirus-Related Cervical Carcinoma
1
Hodgkin Disease
1
Hepatitis B
1
HIV Infections
1
Gliosarcoma
1
Interventions
Temozolomide
111
Radiotherapy
60
Carboplatin
30
Bevacizumab
30
Magnetic Resonance Spectroscopy
28
Carmustine
28
Filgrastim
23
Surgical Procedures, Operative
22
Irinotecan
22
Radiation
17
Lomustine
16
Vincristine
15
Etoposide
15
Specimen Handling
13
Peripheral Blood Stem Cell Transplantation
13
O(6)-benzylguanine
13
Radiotherapy, Intensity-Modulated
12
Procarbazine
11
Erlotinib Hydrochloride
11
Cyclophosphamide
11
Chemotherapy, Adjuvant
11
sargramostim
10
Thiotepa
10
Cisplatin
10
Flucytosine
9
Everolimus
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Granulocyte Colony-Stimulating Factor
8
Vorinostat
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Astrocytoma
×
Tetanus Toxoid
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts